Background: A high prevalence of cancers in metabolic disorders, like metabolic syn-
| INTRODUCTION
Several epidemiological studies have shown consistently that metabolic disorders that are characterized by hyperinsulinemia and insulin resistance, such as obesity and type 2 diabetes mellitus (T2DM), are associated with a significantly increased risk of cancer and cancerspecific mortality. 1 The links that underlie this association are not entirely clear and appear to involve a number of complex mechanisms.
Although insulin is a major mediator of important metabolic functions, it is widely accepted that it might exert mitogenic functions through the activation of different signaling pathways. Hyperglycemia and increased free fatty acids in T2DM also are thought to cause oxidative stress, thus leading to DNA damage. 1, 2 As a meta-analysis has suggested, the relationship between prostate cancer (PC) and T2DM or metabolic syndrome (MetS) is still under discussion. [3] [4] [5] [6] [7] However, a recent study has suggested that pre-existing T2DM also is associated with a higher level of mortality in patients with PC, similarly to other cancers. 8, 9 In this review, the pathological relationship between obesity and/or T2DM with PC is examined, especially from the aspect of the impact of insulin resistance on PC growth.
| EPIDEMIOLOGICAL RELATIONSHIP BETWEEN PROSTATE CANCER AND METABOLIC SYNDROME
In an observational epidemiological meta-analysis that targeted >68 000 men, an increase in the body mass index (BMI) showed a weak correlation with the risk of developing PC (the relative risk was 1.05-fold a 5 kg/m 2 BMI increase). This relationship was much stronger in advanced PC. 10 Additionally, in a large-scale observational study on the relationship between MetS, based on the diagnostic criteria of the National Cholesterol Education Program, and PC, the increased risk of PC was 1.56-fold when more than three components of MetS were met. 11 However, no such relationship was observed in another report. 12 In a prospective study from Sweden, which tracked 2322 patients for 34 years, MetS was shown to be a significant risk factor for the development of PC, after excluding death from the other etiologies. 13 Hyperinsulinemia that is secondary to insulin resistance, as observed in MetS and early-stage T2DM, has been suggested as a possible risk factor in the development and exacerbation of PC. to 2004 in the USA that T2DM is associated with a reduced risk of PC by 16%. 4 However, another study reported that such a risk reduction was observed after 5 years from the onset of T2DM. 14 The relative risk of PC also was reported to be decreased in studies of patients with T2DM who had been affected with T2DM for ≥6-15 years. 15 In patients with long-term and advanced T2DM, pancreatic β-cell exhaustion is assumed to take place and cause the decreased secretion of insulin. As insulin is known to be a growth factor for cancer in general, the reduction of the PC risk may be observed in long-term and advanced T2DM. In addition, serum testosterone (T) concentration has been shown, as described later, to decrease in T2DM. It is thus conceivable that a reduction in serum T in T2DM also could result in a decrease in the risk of developing PC, which is generally accepted to be an androgen-sensitive cancer. However, as described later, it is still controversial at present whether the relatively low concentration of T acts as suppressive or promotive with regard to PC progression.
Androgen-deprivation therapy (ADT), usually by a combination of androgen blockade and luteinizing hormone-releasing hormone agonist is the standard of care for patients with PC. The ADT has been reported to increase patients' visceral fat, thus leading to the risk of MetS and T2DM in observational studies. 16, 17 The increased risk of developing MetS and T2DM leads to an increase in cardiovascular death, and indeed, in Europe and the USA, 30% of the patients with PC died of cardiovascular disease. 18 Although the prognosis of PC is relatively good, a concern with ADT therapy regarding its cardiovascular risk in
Europe and the USA has been raised, but it almost remains unclear in Japan. In a prospective Japanese study 19 that targeted 58 men with PC who were treated with ADT for 6 months, the whole cohort did not show a significant change in arterial stiffness, as monitored with the Cardio-Ankle Vascular Index (CAVI), but 55.2% of the patients did show an increase in arterial stiffness. In addition, the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio was higher in the group with, than without, an increased CAVI after 6 months of ADT, suggesting some impact of ADT on the lipid profile and successive development of arterial stiffness after ADT. However, more evidence concerning the impact of ADT on cardiovascular diseases in Japan is required.
| DOES INSULIN RESISTANCE PROMOTE THE PROLIFERATION OF PROSTATE CANCER?
Increased Concerning the involvement of adipocytokines and free fatty acids that also are related to the pathology of obesity and insulin resistance, leptin is reported to promote the PC cell proliferation in vitro and suppress apoptosis, 30 but the relationship between the serum leptin concentration and PC growth remains unclear. 31, 32 Interestingly, a high concentration of serum adiponectin has been reported to decrease the risk of PC, independently of the BMI and serum C-peptide level. 32 As a mechanism, a direct inhibitory effect of adiponectin on the proliferation of tumor blood vessels 33 and tumor cells 34 has been suggested. The elevation of inflammatory cytokines, such as tumor necrosis factor-α, interleukin-6 (IL-6), and IL-8 in association with
MetS has been suggested to increase the PC risk via nuclear factorkappa signaling. 31, 35 However, saturated fatty acids that increase in the insulin-resistant state have been reported to promote PC growth by enhancing IGF-1 signaling, endoplasmic reticulum (ER) stress, and by impairing the innate immunity. 36 Epidemiologically, it has been reported that the ingestion of polyunsaturated fatty acids of the ω3 series decreases the risk of PC, while the intake of the ω6-type polyunsaturated fatty acids increases the same risk. 37 
| RELATIONSHIP BETWEEN ANDROGENS AND PROSTATE CANCER
The relationship between T and PC is well known to be androgen- reported that patients with low T values in the blood have more advanced PC, with poor differentiation, 42, 43 suggesting that some cases of PC might be rather sensitive to T, even in the low concentration range. However, with such PC progression, an adaptation of AR signaling might function under low or absent androgen levels. 44 
| RELATIONSHIP BETWEEN ANDROGENS AND METABOLIC SYNDROME OR TYPE 2 DIABETES MELLITUS
Many meta-analyses have revealed that 30%-50% of middle-aged and elderly men with T2DM show decreased serum T levels. In a prospective study, men with a relatively high serum T level were reported to show a 42% risk reduction of future T2DM. 45 A similar relationship has been observed between MetS and the serum T level. 46, 47 When the intrinsic serum T value of young healthy adults was lowered by the administration of gonadotropin-releasing hormone (GnRH) analog, an increase in the body fat percentage and a decrease in the resting energy consumption were observed, 48 strongly
suggesting that the decrease in T concentration causes fat accumulation in men. As a fundamental study on the relationship between T and visceral fat obesity, the authors showed that male AR knockout mice exhibited late-onset visceral fat obesity that was related to decreased energy expenditure. 49 In addition, as mentioned earlier, during the course of ADT by GnRH agonists in patients with PC, an increase in body fat leads to MetS and the rapid aggravation of T2DM. 16, 17 Lowered T bioactivity has been reported to increase lipoprotein lipase activity and triglyceride (TG) catabolism in the blood, causing TG uptake into the adipose tissue. 50 The exogenous administration of T decreases the amount of body fat and improves insulin resistance. 50 In addition, the endogenous DHT action system also suppresses the vascular endothelium and arteriosclerosis.
Together with others, the authors have shown that a reduction of endogenous T accelerates the onset and progression of T2DM and arteriosclerosis. 51, 52 Therefore, ADT surely is an important therapy for patients with PC, but it is also unclear whether a low level of T due to ADT can be linked to PC progression and/or castration-resistant PC in the long term by inducing MetS and hyperinsulinemia.
Metabolic syndrome or T2DM is thought to cause low T levels.
Specifically, fat accumulation in the body is considered to suppress gonadotropin secretion, mediated by inflammatory cytokines from adipose tissue or by leptin resistance in the hypothalamus. With this hypothesis, a vicious cycle of low T and fat accumulation has been proposed. 50 
| DRUGS FOR TYPE 2 DIABETES MELLITUS AND PROSTATE CANCER
The oral hypoglycemic agent, metformin, is known for its anti-cancer effect. Metformin has been studied previously in vitro as a possible agent that could have a protective effect against PC or to delay disease progression. [53] [54] [55] [56] Clinical and epidemiological studies have been inconclusive because no impact of metformin use on PC risk 56,57 and a possible beneficial impact on disease progression and survival 58, 59 have been reported, respectively.
Incretin therapy, which includes the delivery of dipeptidyl pepti-
dase-4 inhibitors and glucagon-like peptide (GLP)-1 receptor (GLP-1R)
agonists, has become a popular treatment for T2DM. Recently, much attention has focused on incretin because of its reported tissue-protective effects beyond merely lowering glucose levels. 60 The authors revealed the anti-PC effect of Exendin (Ex)-4, a GLP-1, both in vivo and in vitro. and with the Helsinki Declaration of 1964 and its later amendments.
Informed consent was obtained from all the patients to be included in the study. All the institutional and national guidelines for the care and use of laboratory animals were followed.
